{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:45:41Z","timestamp":1782971141712,"version":"3.54.5"},"reference-count":96,"publisher":"European Respiratory Society (ERS)","issue":"2","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2015,3,20]]},"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>Multidrug-resistant tuberculosis (MDR-TB) is a major global health problem. The loss of susceptibility to an increasing number of drugs behoves us to consider the evaluation of non-traditional anti-tuberculosis drugs.<\/jats:p><jats:p>Clarithromycin, a macrolide antibiotic, is defined as a group 5 anti-tuberculosis drug by the World Health Organization; however, its role or efficacy in the treatment of MDR-TB is unclear. A systematic review of the literature was conducted to summarise the evidence for the activity of macrolides against MDR-TB, by evaluating<jats:italic>in vitro, in vivo<\/jats:italic>and clinical studies. PubMed and Embase were searched for English language articles up to May 2014.<\/jats:p><jats:p>Even though high minimum inhibitory concentration values are usually found, suggesting low activity against<jats:italic>Mycobacterium tuberculosis<\/jats:italic>, the potential benefits of macrolides are their accumulation in the relevant compartments and cells in the lungs, their immunomodulatory effects and their synergistic activity with other anti-TB drugs.<\/jats:p><jats:p>A future perspective may be use of more potent macrolide analogues to enhance the activity of the treatment regimen.<\/jats:p>","DOI":"10.1183\/09031936.00147014","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T03:06:18Z","timestamp":1432868778000},"page":"444-455","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of macrolides for possible use against multidrug-resistant<i>Mycobacterium tuberculosis<\/i>"],"prefix":"10.1183","volume":"46","author":[{"given":"Anne-Fleur","family":"van der Paardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Wilffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onno W.","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiel C.M.","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"van Soolingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjip S.","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G.W.","family":"Kosterink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2015,5,28]]},"reference":[{"key":"2024102023315136000_46.2.444.1","unstructured":"World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva, World Health Organization, 2011."},{"key":"2024102023315136000_46.2.444.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70139-0"},{"key":"2024102023315136000_46.2.444.3","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis460"},{"key":"2024102023315136000_46.2.444.4","unstructured":"World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva, World Health Organization, 2011."},{"key":"2024102023315136000_46.2.444.5","unstructured":"World Health Organization. Global tuberculosis report 2012. Geneva, World Health Organization, 2012."},{"key":"2024102023315136000_46.2.444.6","unstructured":"World Health Organization. Global tuberculosis report 2014. Geneva, World Health Organization, 2014."},{"key":"2024102023315136000_46.2.444.7","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir858"},{"key":"2024102023315136000_46.2.444.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.10.001"},{"key":"2024102023315136000_46.2.444.9","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks371"},{"key":"2024102023315136000_46.2.444.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2004.apm11211-1209.x"},{"key":"2024102023315136000_46.2.444.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00401-0"},{"key":"2024102023315136000_46.2.444.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.143-150.2004"},{"key":"2024102023315136000_46.2.444.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"2024102023315136000_46.2.444.14","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.40.9.2137","article-title":"Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients","volume":"40","author":"Ji","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102023315136000_46.2.444.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.3.515"},{"key":"2024102023315136000_46.2.444.16","first-page":"S14","article-title":"Newer drugs in leprosy","volume":"69","author":"Grosset","year":"2001","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"2024102023315136000_46.2.444.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61962-0"},{"key":"2024102023315136000_46.2.444.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-10"},{"key":"2024102023315136000_46.2.444.19","first-page":"301","article-title":"New developments in the treatment of nontuberculous mycobacterial (NTM) disease","volume":"11","author":"Griffith","year":"1996","journal-title":"Semin Respir Infect"},{"key":"2024102023315136000_46.2.444.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1531"},{"key":"2024102023315136000_46.2.444.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(03)00022-4"},{"key":"2024102023315136000_46.2.444.22","doi-asserted-by":"publisher","DOI":"10.1038\/35101544"},{"key":"2024102023315136000_46.2.444.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2004.07.095"},{"key":"2024102023315136000_46.2.444.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2141"},{"key":"2024102023315136000_46.2.444.25","doi-asserted-by":"publisher","DOI":"10.1007\/BF00295501"},{"key":"2024102023315136000_46.2.444.26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.462"},{"key":"2024102023315136000_46.2.444.27","doi-asserted-by":"publisher","DOI":"10.1159\/000320320"},{"key":"2024102023315136000_46.2.444.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1161-x"},{"key":"2024102023315136000_46.2.444.29","doi-asserted-by":"publisher","DOI":"10.1097\/01.qco.0000160901.71813.fe"},{"key":"2024102023315136000_46.2.444.30","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200709020-00004"},{"key":"2024102023315136000_46.2.444.31","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-007-0016-1"},{"key":"2024102023315136000_46.2.444.32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0196"},{"key":"2024102023315136000_46.2.444.33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-3565(24)35272-3","article-title":"Anti-inflammatory activity of macrolide antibiotics","volume":"292","author":"Ianaro","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2024102023315136000_46.2.444.34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1937"},{"key":"2024102023315136000_46.2.444.35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00149.x"},{"key":"2024102023315136000_46.2.444.36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1542"},{"key":"2024102023315136000_46.2.444.37","first-page":"1041","article-title":"The effect of combined tobramycin-clarithromycin on Mycobacterium tuberculosis isolates","volume":"13","author":"Stoffels","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023315136000_46.2.444.38","first-page":"621","article-title":"In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis","volume":"2","author":"Bergmann","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023315136000_46.2.444.39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2692"},{"key":"2024102023315136000_46.2.444.40","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.3.391"},{"key":"2024102023315136000_46.2.444.41","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.6.885"},{"key":"2024102023315136000_46.2.444.42","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.3.343"},{"key":"2024102023315136000_46.2.444.43","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2008.20.2.202"},{"key":"2024102023315136000_46.2.444.44","doi-asserted-by":"publisher","DOI":"10.1007\/s002849900095"},{"key":"2024102023315136000_46.2.444.45","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1162"},{"key":"2024102023315136000_46.2.444.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2007.05.003"},{"key":"2024102023315136000_46.2.444.47","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1447-1454.2005"},{"key":"2024102023315136000_46.2.444.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00163-1"},{"key":"2024102023315136000_46.2.444.49","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.519-521.2002"},{"key":"2024102023315136000_46.2.444.50","first-page":"580","article-title":"Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs","volume":"2","author":"Abate","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023315136000_46.2.444.51","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200308-1159OC"},{"key":"2024102023315136000_46.2.444.52","first-page":"409","article-title":"Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy","volume":"10","author":"Escudero","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023315136000_46.2.444.53","first-page":"507","article-title":"Management of multidrug-resistant tuberculosis in Italy","volume":"9","author":"Ferrara","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023315136000_46.2.444.54","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.57.9.810"},{"key":"2024102023315136000_46.2.444.55","first-page":"253","article-title":"A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents","volume":"8","author":"Morcillo","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023315136000_46.2.444.56","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.108712"},{"key":"2024102023315136000_46.2.444.57","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00041314"},{"key":"2024102023315136000_46.2.444.58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00474-11"},{"key":"2024102023315136000_46.2.444.59","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.11.2344"},{"key":"2024102023315136000_46.2.444.60","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2827"},{"key":"2024102023315136000_46.2.444.61","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00001913"},{"key":"2024102023315136000_46.2.444.62","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12335"},{"key":"2024102023315136000_46.2.444.63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001300"},{"key":"2024102023315136000_46.2.444.64","first-page":"1182","article-title":"Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast\/Winelands, South Africa, 1992-2002","volume":"12","author":"Shean","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023315136000_46.2.444.65","doi-asserted-by":"publisher","DOI":"10.3201\/eid1209.051618"},{"key":"2024102023315136000_46.2.444.66","doi-asserted-by":"publisher","DOI":"10.1086\/522537"},{"key":"2024102023315136000_46.2.444.67","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2002.1412"},{"key":"2024102023315136000_46.2.444.68","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0574"},{"key":"2024102023315136000_46.2.444.69","first-page":"1373","article-title":"Side effects associated with the treatment of multidrug-resistant tuberculosis","volume":"9","author":"T\u00f6r\u00fcn","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024102023315136000_46.2.444.70","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00179712"},{"key":"2024102023315136000_46.2.444.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800106"},{"key":"2024102023315136000_46.2.444.72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063057"},{"key":"2024102023315136000_46.2.444.73","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1128\/AAC.41.9.2035","article-title":"Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages","volume":"41","author":"Mor","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102023315136000_46.2.444.74","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1128\/AAC.40.10.2375","article-title":"Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin","volume":"40","author":"Patel","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102023315136000_46.2.444.75","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.2.334"},{"key":"2024102023315136000_46.2.444.76","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/AAC.41.6.1399","article-title":"Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers","volume":"41","author":"Rodvold","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102023315136000_46.2.444.77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/j.1875-9114.1994.tb02793.x","article-title":"Accumulation of clarithromycin in macrophages infected with Mycobacterium avium","volume":"14","author":"Mor","year":"1994","journal-title":"Pharmacotherapy"},{"key":"2024102023315136000_46.2.444.78","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.5.719"},{"key":"2024102023315136000_46.2.444.79","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705984"},{"key":"2024102023315136000_46.2.444.80","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00022912"},{"key":"2024102023315136000_46.2.444.81","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki148"},{"key":"2024102023315136000_46.2.444.82","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01297-10"},{"key":"2024102023315136000_46.2.444.83","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01903-13"},{"key":"2024102023315136000_46.2.444.84","doi-asserted-by":"publisher","DOI":"10.1038\/35016103"},{"key":"2024102023315136000_46.2.444.85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030466"},{"key":"2024102023315136000_46.2.444.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.09.018"},{"key":"2024102023315136000_46.2.444.87","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01994-13"},{"key":"2024102023315136000_46.2.444.88","first-page":"203","article-title":"Structure-activity relationships for six ketolide antibiotics","volume":"42","author":"Champney","year":"2001","journal-title":"Curr Microbiol"},{"key":"2024102023315136000_46.2.444.89","unstructured":"U.S. Food and Drug Administration. Telithromycin (marketed as Ketek) Information. www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm107824.htm Date last accessed: September 14, 2014. Date last updated: January 19, 2010."},{"key":"2024102023315136000_46.2.444.90","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-6-200503210-00121"},{"key":"2024102023315136000_46.2.444.91","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831070-00002"},{"key":"2024102023315136000_46.2.444.92","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.302.1.320"},{"key":"2024102023315136000_46.2.444.93","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-007-7211-8"},{"key":"2024102023315136000_46.2.444.94","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00176610"},{"key":"2024102023315136000_46.2.444.95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112433"},{"key":"2024102023315136000_46.2.444.96","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1482"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00147014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:23:17Z","timestamp":1748406197000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00147014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,28]]},"references-count":96,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,7,31]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1183\/09031936.00147014"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00147014","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,28]]}}}